SUPERNUS PHARMACEUTICALS, INC. — Form 10-Q
Filed August 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Jack A. Khattar (President/CEO) and Timothy C. Dec (SVP/CFO) certified the Q2 2026 10-Q for period ended June 30, 2026, filed August 3, 2026. Standard Sarbanes-Oxley Section 302 and 906 certifications affirming financial statement accuracy, disclosure controls effectiveness, and internal control over financial reporting design. No material weaknesses, deficiencies, or fraud disclosed.
Why this rating
Boilerplate executive certification exhibits; standard quarterly SEC compliance. No operational, financial, or strategic changes disclosed.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.